Log In Sign up
The largest database of trusted experimental protocols

Innobia alzbio3 immunoassay

Manufactured by Fujirebio
Visit Supplier
Sourced in Belgium

The INNOBIA AlzBio3 is a laboratory immunoassay product designed to measure specific biomarkers. It utilizes an automated platform to perform the necessary analytical tests.

Automatically generated - may contain errors

Lab products found in correlation

Multiplex xmap luminex platform, by DiaSorin (1 mentions) Luminex platform, by DiaSorin (1 mentions) Xmap luminex platform, by Fujirebio (1 mentions) Luminex 200 platform, by DiaSorin (1 mentions) Innotest enzyme linked immunosorbent assay elisa, by Fujirebio (1 mentions) Nf light elisa, by UmanDiagnostics (1 mentions) Multiskan mk3, by Thermo Fisher Scientific (1 mentions) Phospho tau 181p, by Fujirebio (1 mentions)

13 protocols using innobia alzbio3 immunoassay

1

Cerebrospinal Fluid Biomarkers in Neurodegenerative Diseases

Check if the same lab product or an alternative is used in the 5 most similar protocols
A lumbar puncture was conducted for all participants for the collection of CSF. β-Amyloid1 (link)–42 (link), phosphorylated tau, and total tau protein were measured by INNO-BIA AlzBio3 immunoassay (Innogenetics Inc, Ghent, Belgium), and α-synuclein concentration was measured by ELISA. SPECT with the DAT tracer 123I-ioflupane was acquired at baseline and follow-up visits.23 (link)
Wang L., Cheng W., Rolls E.T., Dai F., Gong W., Du J., Zhang W., Wang S., Liu F., Wang J., Brown P, & Feng J. (2020). Association of specific biotypes in patients with Parkinson disease and disease progression. Neurology, 95(11), e1445-e1460.
+ Open protocol
+ Expand
2

Biomarkers in Neurodegenerative Diseases

Check if the same lab product or an alternative is used in the 5 most similar protocols
A lumbar puncture was conducted for all participants for the collection of CSF. β-Amyloid1–42, phosphorylated tau, and total tau protein were measured by INNO-BIA AlzBio3 immunoassay (Innogenetics Inc, Ghent, Belgium), and α-synuclein concentration was measured by ELISA. SPECT with the DAT tracer 123I-ioflupane was acquired at baseline and follow-up visits.23 (link)
Wang L., Cheng W., Rolls E.T., Dai F., Gong W., Du J., Zhang W., Wang S., Liu F., Wang J., Brown P, & Feng J. (2020). Association of specific biotypes in patients with Parkinson disease and disease progression. Neurology, 95(11), e1445-e1460.
+ Open protocol
+ Expand
3

Multiplexed CSF Biomarker Analysis in ADNI

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
CSF Aβ1–42, t-tau, and p-tau181p were measured using the INNO-BIA AlzBio3 immunoassay kit based reagents (Innogenetics, Ghent, Belgium) in the multiplex xMAP Luminex platform (Luminex, Austin, TX, USA) as previously described.[16 (link)] The CSF data used in this study were obtained from the ADNI files “UPENNBIOMK5–8.csv.” Detailed ADNI methods for CSF acquisition, measurements, and QC procedures were described at www.adni-info.org.
Wei H.C., Li B., Ng K.P., Fu Q.X., Dong S.J., Ba M.W, & Kong M. (2021). Amyloid and tau positive mild cognitive impairment: clinical and biomarker characteristics of dementia progression. Chinese Medical Journal, 134(14), 1709-1719.
+ Open protocol
+ Expand
4

ADNI Baseline CSF Biomarkers

Check if the same lab product or an alternative is used in the 5 most similar protocols
Baseline CSF samples were collected at ADNI clinical centers, frozen at -80 C, and shipped to the ADNI Biomarker Core Laboratory at the University of Pennsylvania. 6 Baseline levels of CSF Aβ 1-42 and phosphorylated-tau 181 (p-tau 181 ) were measured using a microbeadbased multiplex immunoassay (Research Use Only INNO-BIA AlzBio3 immunoassay; Fujirebio, Ghent, Belgium) on the Luminex platform (Luminex Corp., Austin, TX, USA).
Matsuoka T., Oya N., Yokota H., Akazawa K., Yamada K, & Narumoto J. (2020). Pineal volume reduction in patients with mild cognitive impairment who converted to Alzheimer's disease. Psychiatry and clinical neurosciences, 74(11).
+ Open protocol
+ Expand
5

CSF Biomarkers in Subjective Cognitive Decline

Check if the same lab product or an alternative is used in the 5 most similar protocols
Lumbar puncture and cerebrospinal fluid (CSF) sample preparation were performed as described in the ADNI manual (http://adni.loni.usc.edu/research/protocols/biospecimens-protocols/, more details in the Supplementary material). CSF Aβ1–42, t-tau and p-tau were measured using INNOBIA AlzBio3 immunoassay kit-based reagents (Innotest, Fujirebio, Ghent, Belgium). Notably, not all participants had CSF sample data since lumbar puncture is an invasive operation. In this study, 11 out of 66 SCD subjects and 25 out of 64 HC subjects had CSF sample data available (Table 1).
Chen H., Sheng X., Luo C., Qin R., Ye Q., Zhao H., Xu Y, & Bai F. (2020). The compensatory phenomenon of the functional connectome related to pathological biomarkers in individuals with subjective cognitive decline. Translational Neurodegeneration, 9, 21.
+ Open protocol
+ Expand
6

Cerebrospinal Fluid Biomarkers Measurement

Check if the same lab product or an alternative is used in the 5 most similar protocols
In ADNI, CSF procedural protocols have been described previously. INNOBIA AlzBio3 immunoassay (Fujirebio, Belgium) was used to measure CSF AD biomarkers (including CSF Aβ1–42, total tau (tTau), and pTau (pg/ml)). The within-batch precision values were < 10% (5.1–7.8% for Aβ1–42, 4.4–9.8% for tTau and 5.1–8.8% for pTau).
CSF HGF was measured using a multiplex panel. The multiplex panel is based upon Luminex immunoassay technology and has been developed by Rules Based Medicine (MyriadRBM) to measure a range of inflammatory, metabolic, lipid and other disease relevant indices. Quality control (QC) data that is specific for the CSF samples included in this study are the test/retest results for the 16 randomly selected CSF samples (http://adni.loni.usc.edu). Analytes were removed if the mean percentage difference was greater than 35% or the test-retest sample was less than 7 or the mean absolute percentage difference was greater than 60% or if the Bland-Altman slope and intercept significantly differed from zero. Participants who had extreme outliers (< 3-fold or > 3-fold standard deviations (SD) from the mean value) were removed. Finally, 5 participants were removed from the data set.
Zhao L.J., Wang Z.T., Ma Y.H., Zhang W., Dong Q., Yu J.T, & Tan L. (2021). Associations of the cerebrospinal fluid hepatocyte growth factor with Alzheimer’s disease pathology and cognitive function. BMC Neurology, 21, 387.
+ Open protocol
+ Expand
7

PPMI CSF Biomarker Sampling and Analysis

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
CSF biomarkers measured in the PPMI include total unphosphorylated α-synuclein, total tau (T-tau), tau phosphorylated at Thr181(P-tau) and amyloid beta1–42 (Aβ1–42). CSF samples for PPMI were obtained by lumbar puncture. CSF and blood collection and analysis of CSF and serum biomarkers in the PPMI have been described previously [24 (link),27 ].
Details on sample handling, shipment and storage are available in the PPMI biologics manual at ppmi-info.org. As described previously in the PPMI [24 (link),27 ], CSF Aβ1–42, T-tau and P-tau were analyzed using xMAP-Luminex technology and INNO-BIA AlzBio3 immunoassay (Fujirebio-Innogenetics, Ghent, Belgium). CSF α-synuclein and CSF hemoglobin levels were analyzed using commercial immunoassay kits (BioLegend; formerly Covance).
Details of test scores and test direction are included in Supplementary Document 1.
Dinesh D., Lee J.S., Gao X, & Palacios N. (2021). Skin conditions in early Parkinson’s disease. Parkinsonism & related disorders, 84, 40-46.
+ Open protocol
+ Expand
8

Lumbar Puncture for AD Diagnosis

Check if the same lab product or an alternative is used in the 5 most similar protocols
All 27 patients underwent a lumbar puncture to confirm the typical CSF profile of AD pathology with reduced amyloidb1-42 concentrations and raised phosphorylated-and total-tau levels. Amyloidb1-42, p-tau, and t-tau were detected using the INNOBIA AlzBio3 immunoassay kit-based reagents (Innotest, Fujirebio, Ghent, Belgium).
Yao Q., Tang F., Wang Y., Yan Y., Dong L., Wang T., Zhu D., Tian M., Lin X, & Shi J. (2022). Effect of cerebellum stimulation on cognitive recovery in patients with Alzheimer disease: A randomized clinical trial. Brain stimulation, 15(4).
+ Open protocol
+ Expand
9

CSF Biomarker Measurement Protocol

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
CSF collection and procedural protocols have been described previously [30 (link)]. Baseline CSF Aβ1-42, tau, and p-tau181 (pg/ml) were measured using the INNOBIA AlzBio3 immunoassay (Fujirebio, Belgium). The within-batch precision values were <10% (5.1–7.8% for Aβ1-42, 4.4–9.8% for tau and 5.1–8.8% for ptau181, respectively).
Xu W., Zhang C., Li J.Q., Tan C.C., Cao X.P., Tan L, & Yu J.T. (2019). Age-related hearing loss accelerates cerebrospinal fluid tau levels and brain atrophy: a longitudinal study. Aging (Albany NY), 11(10), 3156-3169.
+ Open protocol
+ Expand
10

Quantification of Alzheimer's Biomarkers in CSF and Plasma

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
CSF Aβ42, total tau, and p‐tau181 were measured using the xMAP Luminex platform with INNO‐BIA AlzBio3 immunoassay (Fujirebio) in a single laboratory (AKESOgen; Norcross, GA) following the manufacturer's protocols. Standard samples were run in duplicate for each plate (range pg/mL: 55‐2060 Aβ42, 28‐1610 total tau, 13‐234 p‐tau181), and each test sample was run in triplicate. Average coefficient of variation was 9.6% for Aβ42, 9.2% for total tau, and 8.9% for p‐tau181. Lots of reagents used during these experiments were #404212 and #405221. Plasma AD biomarkers were measured using the Simoa Platform Version 2 Advantage Kit (Quanterix Corp) and were used in a fully automated two‐step sandwich immunoassay as described previously.
19 (link)
Hajjar I., Neal R., Yang Z, & Lah J.J. (2024). Alzheimer's disease cerebrospinal fluid biomarkers and kidney function in normal and cognitively impaired older adults. Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring, 16(2), e12581.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!